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Over the last few years, researchers have started to explore a particular class of compounds 
defined as ionic liquids (ILs) in attempts to use their unique characteristics. Since ILs have a very 
low vapor pressure, these fascinating compounds hold great potential as high performance chemicals 
for several applications in the (bio)pharmaceutical industry. In general, and unlike common organic 
solvents with comparable polarities, ILs are quite compatible with enzymes (enhancing their 
structural and chemical stability) and other proteins, since they can promote higher selectivities, 
faster reaction rates and greater enzyme stabilities in biocatalytic reactions providing, at the same 
time, a path for the structural and functional stabilization of protein entities. ILs appear to enhance 
the delivery of macromolecules, particularly protein entities, and their interactions with ILs will 
be tackled in detail in this review paper.
Keywords: ionic liquids, structural and functional stabilization, protein stability, 
biopharmaceutical applications, transdermal drug delivery
1. Introduction
Commonly, ionic liquids (ILs) are organic, highly 
viscous low volatile salts, displaying low melting points 
(arbitrarily defined as compounds with melting points 
below 100 °C), consisting entirely of charged species 
(ions) and some being liquid at room temperature.1-5 The 
search for new, different ILs, has progressively led to 
the development of three generations of ILs.6 The first 
generation was focused mainly on their unique intrinsic 
physicochemical properties (such as density, viscosity, 
conductivity, solubility, and high thermal and chemical 
stabilities). The second generation of ILs made it possible 
to tailor some of these physicochemical properties, allowing 
applications as lubricants, energetic materials (in selective 
separation and extraction processes), and as “greener” 
reaction solvents. The third (and most recent) generation of 
ILs involve active pharmaceutical ingredients (API), which 
are being used to produce ILs with biological activity.6 
Additionally, ILs are thermodynamically stable (stable at 
high temperatures and pressures), and with the development 
of the third generation of ILs, it was shown that they may be 
even produced from inexpensive and generally recognized 
as safe (GRAS) starting materials.7 These characteristics 
in association to interesting solvent properties,1-3,8-13 in 
particular, because ILs are able to dissolve some apolar 
molecules as well as some very polar ones, make them 
promising compounds for the pharmaceutical processing. 
Insights into Protein-Ionic Liquid Interactions Aiming at Macromolecule Delivery Systems J. Braz. Chem. Soc.1984
In addition to their unique properties, ILs are considered 
“tailored or designer solvents” because their physico-
chemical properties (viz. viscosity, density, miscibility 
with other solvents, melting point) fully depend on their 
structure and can be adjusted by altering the anion and/or 
the cation.14 The tunable nature of ILs has led to their use 
in many novel applications, from the material science to the 
more innovative application in life sciences and medicine.15 
A large number of studies on the properties and applications 
of ionic liquids have been performed in the last decades, and 
interesting discussion reviews have been already published, 
namely in life sciences, food and health applications, and 
towards the development of IL-nanosystems.16-26
The structure of ILs is totally different from that of 
any other (classic) solvent made of molecules, whose 
properties depend upon the interactions between their 
constituent molecules. If such interactions between the 
molecules constituting the solvent are strong, the solvent 
is termed “polar” (e.g. water and alcohols with small 
alkyl chains). On the other hand, if such interactions 
are weak, the solvent is termed “apolar” (e.g. hexane, 
heptane, among others). Hence, one distinctive feature of 
ILs lies in the fact that they are not made of molecules, 
but ions. A particular substance is in the liquid state when 
the interactions between its constituent species (either 
molecules or ions) are stronger than those existing in 
the gaseous state, but weaker than those that lead to the 
solid state. Due to these energetic interactions, the vast 
majority of liquids is comprised of neutral molecules 
since the presence of charged species determines the 
existence of ionic interactions, which are typically 
strong enough to drive the substance to a solid state 
of aggregation.1,27,28 If one compares a typical IL, e.g. 
1-ethyl-3-methylimidazolium ethylsulfate, with a typical 
inorganic salt, e.g. NaCl, it becomes obvious why there 
is a difference between them (see Figure 1).
The IL has a significantly lower symmetry. Furthermore, 
the charge of the cation as well as the charge of the anion 
is distributed over a larger volume of the molecule via 
resonance. As a consequence, solidification of the IL will 
occur at lower temperatures. In some cases, especially if 
long aliphatic side chains are involved, a glass transition 
is observed instead of a melting point. The strong ionic 
(Coulomb) interaction within these substances results in a 
negligible vapor pressure (unless decomposition occurs), 
a non-flammable substance, and in a high thermally, 
mechanically as well as electrochemically stable product. In 
addition to this very interesting combination of properties, 
ILs offer other favorable properties such as very appealing 
solvent properties and, depending on their particular ion 
composition, miscibility or immiscibility with water 
and organic solvents that result in biphasic systems. The 
choice of the cation has a strong impact on the properties 
of the IL and will often define its stability. The chemistry 
and functionality of the IL is, in general, controlled by 
the choice of the anion. ILs are widespread in chemistry, 
although not generally described as ILs, but known by their 
features, such as their ability to act as ionic surfactants.29 
Thus, recently, ILs bearing long alkyl-chains were termed 
surface-active ionic liquids (SAILs) due to their intrinsic 
amphiphilic nature (which includes some of charged 
surfactants that are liquid at low temperatures). The peculiar 
aggregation behaviors of SAILs have drawn great attention 
in the field of colloid and interface chemistry. SAILs also 
have a respectable and important scope in pharmaceutical 
fields due to their ability to enhance the permeability of 
drugs across biomembranes and, in this manner, to act as 
better drug carriers as compared to conventional cationic 
surfactants,1,30,31 in particular because they are liquids, their 
solubilization power for very hydrophobic substances in 
water is greatly intensified.29
An in-depth analysis of the nature of interactions in 
ionic substances shows that they have a wide degree of 
variation, enabling the preparation of fluids exhibiting 
different ionic character (i.e., ILs). ILs may thus be 
described as organized three-dimensional networks of 
anion and cation species, both in the (semi)solid and liquid 
states, as a result of different strong, but screened short-
Figure 1. Comparison between a typical inorganic salt (a), e.g. sodium chloride, and a typical ionic liquid (b).
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ranged electrostatic interactions similar to “classical” 
high-temperature molten salts. Such organized three-
dimensional network structures are maintained when ILs 
are dissolved in solvents with moderate to low polarities, 
a behavior that characterizes such salts as supramolecular 
structures.1,27,28 Different ILs display different properties as 
a result of all weak interactions present. Hence, although 
an understanding of such force balance is not trivial, it is 
of utmost importance for an enlightenment of the nature 
of ILs and facilitating both the planning and design of new 
ILs with specific properties. Ionic interactions do play a 
major role in the understanding of the physicochemical 
and biological phenomena involved in protein folding/
unfolding and refolding processes.8,32-34 The potential 
applications and advantages of ILs have now been well 
recognized by the scientific community, in particular due 
to the dynamic and tunable potential of ionic species in 
liquid phase. In this context, because ILs display low 
melting points and are entirely composed of chemically 
distinct ions, they have been progressively changing the 
picture of protein/enzyme stability in conventional organic 
solvents,35,36 some of them being now generally considered 
as more biocompatible alternatives to the volatile organic 
compounds (VOCs).25,37,38 Although some ILs may be less 
toxic than VOCs, there are ILs (particularly imidazole-
based ones) that are more toxic than VOCs.25,37,38 Salt 
ions are classified as being either kosmotropic (structure 
makers) or chaotropic (structure breakers), according 
to their relative abilities to induce the (re)structuring of 
water molecules. Small ions (kosmotropes), due to their 
high charge densities, promote a strong electrostatic 
ordering of nearby water molecules by breaking hydrogen 
bonds between them. In contrast, large ions (chaotropes) 
possess low charge densities and, therefore, surrounding 
water molecules are mostly hydrogen-bonded. Protein 
stability and enzyme activity/stability in aqueous solution 
can be strongly influenced by the type of salts present 
therein.34,35,39,40 IL-induced stabilization/destabilization 
phenomena of the protein entity’s nanoenvironment are 
just starting to be tackled.35,41-49 In this context, several 
researchers have reported that a specific combination 
of a chaotropic cation and a kosmotropic anion possess 
the ability to stabilize proteins.35,50 One of the most 
interesting feature of ILs to control the stability, 
selectivity and activity of enzymes, lies in the fact that 
they can interact both with water and protein surface 
(see Figure 2),15 and thus, they can be used in a wide 
range of (bio)applications, such as: protein aggregation 
and solubilization; crystallization; enzymes enhancers or 
stabilizers;52 in the control of protein reversible folding/
unfolding; activation and denaturation.51
Recently, both ILs and deep eutectic solvents (DES, a 
mixture of charged and neutral species, either in equimolar 
or imbalanced ratios that, when combined, have a much 
lower melting point than the individual components) 
were found to increase drug solubility, improving drug 
formulations, specially, applied as carriers for topical drug 
delivery.35,53-61
2. Relevant Physicochemical Properties of ILs
As recently demonstrated,62 the properties of ILs at 
molecular level allows a modulation of different levels 
of organization (nanoscale and microscale). Due to this 
ordering and organization (not observed in common 
molecular liquids), ILs exhibit unique physicochemical 
characteristics, including (but not limited to) quite low 
melting points, negligible vapor pressures and high 
electric conductivity,1,16,59,63 which have attracted more 
and more attention for numerous applications.15 Due to the 
wide range of potential applications of ILs, below some 
important physicochemical characteristics are reviewed, 
in particular because ILs have the capability to exert 
positive effects on the stability, solubility and activity of 
biomacromolecules such as protein entities. Enzymes, for 
example, remain trapped in ILs, which allow both their 
recovery and reuse for continuous processing, reducing 
the overall process cost. Nevertheless, it is important to 
note that not all ILs are appropriate for biocatalysis, and 
their proper design is the key for the success of ILs-based 
biocatalysis. Thus, the activity, specificity and stability 
of an enzyme in ILs will depend on specific solvent 
characteristics such as polarity, hydrophobicity, viscosity, 
hydrogen-bonding capability, solvent miscibility and 
presence of impurities.14
Figure 2. Putative interactions (dotted lines representing hydrogen 
bonding and arrows representing strong Coulomb interactions) between 
solvent species with a protein surface, at high ion concentrations (adapted 
from reference 51).
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2.1. Ability to establish hydrogen-bonds
Traditional (solid) salts are able to efficiently pack their 
constituent ions to form a crystal lattice. As previsously 
referred, for ILs the cations are asymmetrically substituted 
with alkyl groups of different chain lengths to prevent 
packing of the cations/anions into a crystal lattice.1,2,64 ILs 
are formed by a widespread network of cations and anions 
that are connected by both ionic interactions and hydrogen 
bonds, which are highly significant for the IL organization.62 
For this reason, ILs are also named “hydrogen-bond 
polymeric supramolecules”.65 The insertion of other 
molecules in that network allows the existence of both polar 
and non-polar regions within the IL structure.14,30 Three-
dimensional networks in ILs are thus formed due to the 
establishment of hydrogen bonds between their constituent 
cations and anions. For example, in imidazolium-
based ILs (such as 1-butyl-3H-benzoimidazolium 
bis-(trifluoromethylsulfonyl)imide, [BzBIm][NTf2]; 
1-butyl-2-phenyl-imidazolium bis(trifluoromethylsulfonyl)
imide, [BPhIm][NTf2]; 1-benzyl-3-butyl-imidazolium 
bis-(trifluoromethylsulfonyl)imide [BnBIm][NTf2]; 
butyl methyl imidazolium bromide [BMIM]Br; 1-ethyl-
3-methylimidazolium, 1-butyl-3-methylimidazolium, and 
1-octyl-3-methylimidazolium)66-68 each cation interacts 
with three anions and each anion interacts with three 
cations, forming a three-dimensional structure.69 When a 
biomacromolecule is placed in contact with such network, 
polar and non-polar regions are formed resulting in a close 
interaction between the biomacromolecule and the IL.14,69,70 
As example, when a protein entity interacts with an IL, the 
hydrogen-bonded three-dimensional network protects the 
protein from unfolding.1,8,32,71
On the other hand, the nucleophilicity of ILs is also 
determined by their ability to form hydrogen bonds: 
the greater this ability, the greater is the basicity and 
the stronger is the nucleophilicity.9,72,73 The basicity 
and nucleophilicity of the hydrogen bonds established 
with the anions also affects protein stability in IL-based 
solvents.35,41,74,75 In general, anions forming hydrogen 
bonds with lower basicities and nucleophilicities are more 
protein-compatible, since low hydrogen bond basicities and 
nucleophilicities minimize both their interferences with the 
internal hydrogen bonds in the protein three-dimensional 
architecture and the interaction with positively charged sites 
in the protein domain. Thus, the use of these ILs as solvent 
media for protein can reduce the tendency to occur relevant 
protein structural changes,41,74-77 allowing the stabilization 
of the protein moiety.34 In short, hydrogen bonding could be 
one of the keys to understanding the interactions between 
proteins and ILs (see Figure 2).
2.2. Hydrophilicity/hydrophobicity
“Hydrophobicity” could be considered as a subset idea 
of “polarity”. It is, however, important to diferentiate the 
former concept from the latter because the former is often 
related to the miscibility with water. The hydrophobicity of 
ILs can be quantified by the log P scale. In general, ILs are 
very hydrophilic (e.g. [C2mim] C2H5SO4, [C2mim] Cl)78 in 
nature based on their negative log P values; nevertheless, by 
convention, one usually refers to those ILs that are poorly 
miscible with water as hydrophobic ILs.35 Examples78 of 
hydrophobic ILs include 1-ethyl-3-methylimidazolium 
([C2mim]) bis-(trifluoromethanesulfonyl) imide ([NTf2]), 
1-n-butyl-3-methylimidazolium ([C4mim]) [NTf2], and 
1-n-hexyl-3-methylimidazolium ([C6mim]) [NTf2]. 
Generally, protein entities are more stable in more 
hydrophobic ILs than in highly hydrophilic ILs. This is 
due, on one hand, to the fact that hydrophobic ILs do not 
remove the essential hydration layer of water molecules 
from the biomacromolecule9,34,79,80 and, on the other hand, 
to the fact that in hydrophobic ILs the protein stays in 
suspended (rather than dissolved, inactive) form.14,77,81 
Increasing the relative hydrophobicity of ILs increase 
their stability, activity and enantioselectivity aptitudes 
over proteins/enzymes. As an example, ILs based on high 
water-soluble anions (smaller anions, such as chloride) can 
enter in the protein core, destabilizing the macromolecules 
structures.82,83 On the opposite, ILs highly hydrophobic 
cause a marked decrease in the rate of enzyme-catalyzed 
reactions promoted by a thermodynamic stabilization of 
the substrate(s) to a ground state.35,84-86
2.3. Effects of constituent cations and anions
Generally, the constituent cations and anions of ILs do 
play an equal role in stabilizing protein entities.84,87,88 As the 
traditional high melting salts, the ability of ILs to stabilize 
proteins are generally correlated with the well-known 
concept of kosmotropicity/chaotropicity. The Hofmeister 
ion series (a classification of ions in order of their ability 
to salt-out or salt-in proteins) influences the interaction of 
cations and anions of different salts with proteins, and such 
interaction depends on the kosmotropic and chaotropic 
properties of such cations and anions constituting the 
ILs.33,39,89 This mechanism appears to result from specific 
interactions between ions and protein moieties, and ions and 
the water molecules directly contacting the protein moieties 
may be more important. Kosmotropes (such as, for example, 
1-butyl-3-methylimidazolium ([BMIM]+))90 are considered 
as structure-maker because they increase the stability of 
protein entities in solution. On the other hand, chaotropes 
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(such as, for example, 1-ethyl-3-methylimidazolium 
([EMIM]+))90 are considered structure-breakers since they 
decrease the stability of proteins in aqueous media.35,91 A 
combination of chaotropic (weakly hydrated) cations and 
kosmotropic (strongly hydrated) anions allows to study the 
interaction(s) between protein entities and ILs.30,92 Anions 
are highly polarizable, and thus are more prone to hydration 
than cations are,35,93,94 thus exhibiting a more dominating 
effect and being more efficient than the latter. Mainly, the 
IL impact on the protein structural conformation seems 
to be a result of interaction between ILs and the aqueous 
environment surrounding the protein.15 Thus, when a protein 
molecule is dissolved in an aqueous solution, it has many 
charged (hydrophilic) groups on its surface responsible 
for interacting with the ions in solution.34,95 Such charged 
groups strongly interact with chaotropic anions (such as 
[SCN]−) and kosmotropic cations (such as Na+ or K+),41 
although it is not yet clear how the hydrophobicity of 
ILs influences the kosmotropicity.35,39 However, due to 
the high number of different interactions that IL ions can 
establish, their classification as kosmotropic or chaotropic 
is often quite complex and difficult.15,96,97 Thus, considering 
the ongoing controversial discussion on the origin of 
Hofmeister series, Friedman98 recommended the use of the 
expression “specific ion effect” instead of other ambiguous 
terms such as “Hofmeister effect”, “Hofmeister series”, 
“lyotropic effect” and “lyotropic series”.
In aqueous solutions, protein molecules might interact 
with solvent molecules and ions through a diversity of 
hydrophilic, polar, or charged moieties, like dehydrated, 
chaotropic amide and amino groups, and the hydrated, 
kosmotropic carboxyl groups. Chaotropic anions have a 
greater affinity towards chaotropic amide of the peptide 
group, while the interaction between kosmotropic cations 
and the kosmotropic carboxyl moiety is weak due to the 
presence of water molecules in their nearest hydration 
shells. This explains the opposite tendency of cations and 
anions in influencing protein stability, and the stronger 
effect of anions compared with that of cations.35,39,41 
However, it is also important to take into consideration 
that the water molecules “clusters” around the protein 
are highly significant to correct and maintain the protein 
function (hydration of the protein backbone), and thus it 
seems that water also has an important role as mediator of 
some effects of ILs over proteins.15
2.4. Effects of cation alkyl chain length
The size of the alkyl chains in the cations of ILs exerts 
a dramatic effect upon the stability and activity of proteins/
enzymes. Some researchers35,45,99-101 have reported that ILs 
possessing long alkyl chains in their constituent cations 
induce a destabilizing effect on proteins and, in particular, 
enzymes. However, some examples can show exactly 
the opposite behavior. As for example, Jha et al.102 have 
shown unexpected effects of the alteration of structure 
and stability of myoglobin and hemoglobin in ammonium-
based ILs. In that study, the authors revealed that less 
viscous ILs carrying smaller alkyl chains induced stronger 
destabilization of heme protein, maybe due to stronger 
interactions with hydrophobic regions of the protein. It has 
been reported that protic ILs,42 such as alkylammonium 
salts, preserve the stability of proteins in aqueous solution 
at high temperatures, and that amyloid fibrils of proteins 
(formed by normally soluble proteins, which assemble to 
form insoluble fibers that are resistant to degradation) are 
dissolved in protic ILs and become refolded by dilution in 
aqueous solution.1,32,100,103 On the other hand, aprotic ILs act 
not only as inhibitors of protein aggregation, but also as 
protective agents for the native, three-dimensional construct 
of protein entities and accelerate the refolding of thermally-
denatured proteins.8,14,32,104 Huddleston et al.12 reported that, 
notwithstanding their high polarities, most ILs commonly 
used in biocatalytic processes are hydrophobic in nature 
due to the presence of large alkyl substituents in the cation 
molecule(s). For example, 1-hexyl-3-methylimidazolium 
hexafluorophosphate is more hydrophobic14 than 1-butyl-
3-methylimidazolium hexafluorophosphate,14 and thus 
more efficient in some biocatalysis.
3. Relevant Biopharmaceutical Properties of 
ILs
ILs are receiving much attention due to their wide 
range of applications in pharmaceuticals, viz. as solvents 
for poorly soluble (macro)molecules, drug reservoirs, drug 
carriers, antimicrobial agents, antibiofilm agents and iono 
gels (see Figure 3).2,106
Several ILs were found to exhibit antimicrobial properties 
when acting on biofilm-forming Gram-negative pathogenic 
bacteria such as Pseudomonas aeruginosa (ATCC15692) 
and Salmonella enterica serovar Typhimurium LT2.64 
These authors performed a comprehensive study on 
several synthesized ILs (viz. tetraalkylphosphonium-oleate, 
tetraalkylphosphonium-hexanoate, tetraalkylphosphonium-
geranate, choline-bistriflimide (NTf2), 1-butyl-
1-methylpyrrolidinium ((BMP)-NTf2), benzethonium-
ZnCl2-BMP-NTf2 (BZBN), 1-hexyl-3-methylimidazolium 
chloride (HMIM-Cl), choline-oleate, choline-hexanoate, 
choline-geranate, choline-malonate, and choline-urea) 
reporting their cytotoxicity effects on mammalian cell 
lines, their skin irritation potential and the properties of 
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those ILs for transdermal drug delivery, and succeeded in 
treating a biofilm on a skin-wound model. In their work, 
Zakrewsky et al.64 showed that choline geranate acts as a 
multipurpose compound, exhibiting excellent antimicrobial 
activity, minimal toxicity to both epithelial cells and skin, 
and effective permeation enhancement for drug delivery. 
The biological outcome of ILs, including transdermal 
delivery, antibacterial activity and cytotoxicity, was 
attributed to the chemical properties of their constituent 
cations and anions.64 ILs are able to solubilize amphipathic 
molecules and, in this way, act as ideal solvent systems 
for topical and transdermal drug delivery (see Figure 3). 
When compared to traditional organic solvents with small 
alkyl chains such as ethanol, ILs can be properly designed 
to be much less toxic to human cells,64,104,107 addressing a 
major issue associated with solvent-induced skin irritation, 
a typical situation occuring with the application of many 
topical formulations. Some physicochemical properties of 
ILs impart them an innate antibacterial activity, most likely 
because these liquids disrupt both charged and hydrogen-
bond networks typically found within polypeptides and 
proteins, polynucleotides and polysaccharides.8,64,108-111 
Biofilms (or microbial cities) are a major cause of chronic 
wounds and malignant degeneration, often persisting in the 
periphery of an actual wound, beneath an intact and healthy 
skin layer, with the difficulty of their treatment being largely 
due to the outermost layer of the skin, the stratum corneum, 
which acts as a natural barrier for drug delivery.9,106,112 A 
question then arises: when considering ILs as bacterial 
biofilm control strategies, how “dead bacteria” is really 
“dead bacteria”? Once the bacterial biofilm is disrupted, the 
penetration of antibiotics or other antimicrobial moieties 
is enhanced, leading to restoration of dispersed pathogen 
cells back to normal antibiotic susceptibility.
3.1. Use of ILs in transdermal applications
According to the Centre for Disease Control (CDC), in 
the United States of America, more than three quarters of all 
bacterial infections in humans are associated with bacterial 
biofilms, while more than 65% of hospital-acquired 
infections are associated to bacterial biofilms. Biofilms are 
densely packed communities, or cities, of microbial cells 
that grow on both living and inert surfaces. When bacteria 
form biofilms, they secrete and surround themselves 
with a dense polymeric matrix that makes them 50-1000 
times more resistant to treatment with antibiotics.113,114 
Considering these impressive numbers, it is evident to 
seek new transdermal delivery systems, which emphasize 
the full potential that can be triggered by the use of ILs, 
with massive therapeutic benefits, by simply disrupting 
bacterial biofilms and facilitating infection targeting 
by antimicrobial molecules. Transdermal drug delivery 
systems have been recognized as possible non-invasive 
routes of drug administration, with several benefits, as 
for example, avoiding first-pass metabolism, allowing 
nonstop therapeutic action and better patient acquiescence. 
Nevertheless, the outmost layer of the epidermis, the 
stratum corneum, offers an outstanding barrier to the 
absorption of pharmaceutical compounds, associated to 
the exceptional ordered structure made up of multiple 
lipid bilayers and surrounded corneocytes.106,115-117 Stratum 
Figure 3. Relationship between ILs and poorly soluble (macro)molecules in the development of IL-protein formulations for transdermal delivery (adapted 
from reference 105).
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corneum serves as a natural barrier to most therapeutical 
agents, hiding a protective biofilm that shelters thriving 
pathogenic bacteria. Under such double-layer, like a 
protective tent over a colony of harmful bacteria, biofilms 
make the treatment of skin infections especially difficult, 
thus making pathogenic bacteria particularly dangerous 
via enhanced antibiotic resistance.64,106,112,118 Traditionally, 
biofilms and skin barriers have been combated with bleach 
or other topical formulations, but these tend to irritate the 
skin and perform poorly as platforms for transdermal drug 
delivery. Some ILs have therefore arised as a potential 
“magic” solution for the effective disruption of biofilms, 
neutralizing pathogens and enhancing the transdermal 
delivery of antimicrobials into the deeper layers of the 
skin, while exhibiting minimal (or virtually nil) cytotoxicity 
effects on human cell lines.2,64,118 Such peculiar and highly 
viscous ILs are able to defeat both the tricky defenses of 
bacteria (via effective biofilm disruption) and skin (via 
transient destabilization of the stratum corneum) and, in 
this way, allow antimicrobial molecules to reach infected 
sites that otherwise could lead to discomfort, amputations 
and, sometimes, death. Hence, ILs have the potential to 
treat chronic wounds and malignant wound, which often 
result from the onset of bacterial biofilms. Recently, 
choline geranate emerged as a multipurpose IL since it 
exhibits excellent antimicrobial activity,64,106,118,119 minimal 
toxicity to epithelial cells as well as to skin, and effectively 
enhances permeation for transdermal drug delivery. 
Choline geranate proved to be highly effective in the 
eradication of established biofilms of Salmonella enterica 
and Pseudomonas aeruginosa, increasing the delivery of 
cefadroxil into the deeper tissue layers of the skin without 
inducing skin irritation.64,118 Other approaches of the use 
of ILs in transdermal applications15 were already reported: 
the use of active pharmaceutical ingredients-ionic liquids 
(API-ILs), that consists in turning a drug into a salt, a 
common and easy way to increase the solubility of drugs;120 
preparation containing fatty acid-based ILs;121 assembled 
formulations composed of drugs and aliphatic carboxylic 
acids and aliphatic carboxylic amines.122
All these studies clearly highlight the potential of ILs for 
the simultaneous enhancement of topical drug delivery and 
antibiotic activity. The hunt for new antimicrobial agents 
has now a new ally which, while protecting and stabilizing 
bioactive (and potentially antimicrobial) protein entities, 
enhances their permeation into the deeper layers of the 
skin (epidermis and dermis) to combat afflictions such as 
acne, eczema and diabetic ulcers which, otherwise, may 
get infected and develop an armored layer of bacterial cells 
(i.e., a bacterial city) that is quite difficult to defeat. While 
some ILs are intrinsically antimicrobial and others can 
transport drugs through the layers of the skin, some display 
both properties, such as choline geranate. The rationale 
underlying the mechanism of action of ILs is probably 
linked to the disruption of the polysaccharide-based shell 
excreted by bacteria that characterize the bacterial cities 
known as biofilms, although the exact mechanism through 
which this happens is not fully clear. Hence, a deeper 
understanding of how ILs disrupt such bacterial biofilms 
is of utmost importance. Once applied on the surface of the 
skin, it is likely that the IL molecules slip in between the 
fatty compounds that make up skin cells, creating transient 
tiny openings through which bioactive molecules (carried 
by the IL) can permeate.
4. Protein Stability and Stabilization in the 
Presence of ILs
Folding of proteins and their functional significances 
are crucial for the existence of a living organism. Their 
functioning is highly dependent of the maintainance of 
protein secondary structure (α-helices, β-sheets and coil 
regions), which are held together through a complex 
balance of hydrogen bonds, disulfide bridges, hydrophobic 
and ionic interactions.51 Although the stability of proteins 
remains as a long-standing unsolved puzzle in protein 
science, their importance is obvious for biotechnological 
and medical applications.8 Proteins are a particularly 
heterogeneous class of biomacromolecules which, when 
displaced from their native (physiological) environments, 
are frequently quite unstable34,117,123,124 due to disruption 
of the weak interactions (including ionic interactions, 
hydrogen bonds and hydrophobic interactions) that are 
primordial for the maintainance of the protein tertiary 
(three-dimensional) structures.125,126 Thus, it is quite obvious 
that by changing the solvent conditions (such as viscosity, 
temperature, pH, ionicity, buffering conditions), the 
protein secondary structure can be significantly affected.51 
Additionally, despite the unstability of both their structural 
integrity and activity, it is expected that purified proteins 
can be stored for extended periods of time. The degree of 
storage stability may fluctuate from a few days to several 
months or even years, being highly dependent on the nature 
of the protein and/or the storage environment.
4.1. How to counteract protein inactivation
Protein aggregation is one of the most important 
problems during production and storage in industrial 
processes and is, therefore, among the major causes of 
economic losses in biotechnology and pharmaceutical 
factories: a variety of proteins, e.g. insulin, coagulation 
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factors, interferons and antibodies are currently available 
for pharmacological treatment of a widespread range of 
diseases, such as diabetes, hemophilia, multiple sclerosis 
and cancers.4,123 In particular, protein aggregation easily 
occurs upon exposure of the hydrophobic amino acid 
moieties, which are usually buried inside the core of 
the three-dimensional architecture of native proteins, a 
phenomenon that becomes a major problem due to the 
fast-irreversible protein inactivation. Thermal denaturation 
of proteins is a serious problem not only in the separation 
and storage of proteins, but also during the processes 
of biotransformation, biosensing, drug production, and 
food manufacturing. Hence, several strategies have been 
proposed in order to prevent thermal denaturation of 
proteins,34,39,106,125,127-136 which can include, for example, 
chemical modification, multipoint covalent immobilization, 
genetic modification, addition of stabilizing agents, among 
others.34,106 The main goal when manufacturing protein-
based commercial products consists in obtaining a stable 
and correct protein folding with full functionality.4,8,32,137
4.2. Potential role of ILs in protein stabilization
ILs have shown excellent promise as both solutes 
and solvents for stabilizing protein entities at room 
temperature,14,104,123,125,138 or even to be applied as aggregation 
inhibitors for protein solutions.139 Several enzymatic 
systems have been assessed in neat ILs or IL solutions: such 
enzymatic structures include numerous hydrolases (e.g. 
lipases, proteases, thermolysin, α-chymotrypsin, lysozyme, 
β-glycosidase, cellulase, epoxide hydrolase and penicillin 
amidase), oxidoreductases (e.g. horseradish peroxidase, 
alcohol dehydrogenase, laccase and lignin peroxidase) and 
lyases (e.g. oxynitrilase).35,140
Because many advanced (bio)pharmaceuticals are 
protein-based, namely those from recombinant origin, 
the stabilizing and solubilizing abilities of ILs show great 
potential to provide advances in the formulation of liquid 
solutions of therapeutic proteins. Therapeutics based on 
proteins (either native or recombinant) has demonstrated 
significant efficacies in controlling and/or eliminating 
certain chronic diseases.123 Differently from traditional 
small-molecule-based drug therapies, a substantial hurdle 
in the development of protein-based (bio)pharmaceuticals 
is related to the maintenance of the active three-dimensional 
conformation of the protein entity, not only throughout 
processing, but also during storage.34,138
Since ILs do not exhibit significant vapor pressures, 
have high thermal stability and a wide range of polarities,8,16 
they appear as suitable and effective platforms for carrying 
out advanced biological reactions. In addition, due to their 
tailoring properties by simply altering the cations (acting 
on the alkyl chains, either via modification of the length or 
the presence of hydrophobic groups) and anions (varying 
either the degree of charge delocalization or its hydrogen 
bonding ability),3,4,64,141,142 ILs can be properly designed 
and adjusted for a specific biological application. Other 
IL properties such as melting point, viscosity, density, and 
hydrophobicity may be also quite valuable, since these 
may be varied by making simple changes to the structure 
of the ILs’ constituent ions.8,14,125,141,142 A high viscosity 
is probably inherent to ILs, since strong intermolecular 
forces between their constituent ions promote high 
viscosity indexes. For ILs, the strong forces prevailing are 
charge-charge interactions, but weaker interactions such 
as van der Waals forces also occur between ions. Thus, 
despite the stronger charge-charge interactions, reducing 
van der Waals interactions and consequently the surface 
area of their constituent ions (namely by reducing their size) 
a slight decrease on the viscosity can be achieved.14,76,142 
The ability to modulate the individual components making 
up ILs presents an advantageous framework for tuning 
secondary and tertiary physicochemical characteristics of 
protein entities without losing their primary function.8,58
4.3. Protein-IL interactions
The problems of protein aggregation and structural 
stability are not limited to the manufacturing processes, 
though. Several research works are focused in the study of 
the ability of ILs to in vitro solubilize and stabilize proteins 
for extended periods of time,123,143-145 by reverting some 
aggregation processes and improving the in vitro refolding 
of denatured proteins.4,14,32,140,146,147 Recently, Balcão and 
Vila34 have suggested that the rationale underlying the 
stabilizing effect of protein entities due to an increased 
viscosity of their surrounding nanoenvironment is, in fact, 
the slowing down of the migration of protein domains from 
the active conformation into the inactive one. The decrease 
of overall dynamics of the solvent and dissolved protein 
by the increase of viscosity is a key for the stabilization of 
proteins, and thus, this mechanism is in total agreement 
with the high viscosity of ILs and their protein-stabilizing 
properties.19,140,142
For low hydration levels of ILs, however, and particularly 
in the case of short-chained hydrophilic ILs, there is a large 
disturbance in the protein’s three-dimensional architecture. 
Notably, hydrophilic ILs are thought to act as denaturants for 
several globular proteins only at high concentrations.14,39,140,148 
The essential shell of water molecules for protein hydration 
is stripped off from the protein entity by small-chained 
hydrophilic solvents, leading to unfolding of the biomolecule 
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and concomitant exposure of the core hydrophobic residues, 
whereas hydrophobic solvents keep the protein moiety 
flexible and in active conformation,1,32,34,35,125,149 with the 
hydrophobic residues buried deep inside its core. On 
the other hand, the interactions of protein moieties with 
ILs are dominated by Coulomb interactions with anions, 
with the second largest contribution stemming from van 
der Waals interactions with cations. The strength of the 
protein-ion interaction is largely determined by both the 
size of the ion and the magnitude of the surface charge 
of the ion.8,140,150 The rationale underlying the mechanism 
for protein stabilization in ILs is interesting. Basically, the 
protein stabilization using ILs arises from their solubility, 
polarity and viscosity effects, which is in clear agreement 
with the work published by Balcão and Vila.34 However, 
it is important to note that the protein can be stabilized or 
destabilized. As example, the high polarity can reduce the 
water associated with protein, but at the same time due to 
the high-water content in the bulk phase the viscosity is 
reduced, increasing consequently the protein mobility (and 
its biological activity).151 The enhanced stability of proteins 
in ILs such as 1-butyl-3-methylimidazolium chloride 
([Bmim] Cl) rules out the prediction that these ILs are also 
denaturants or destabilizers for the protein structure.152,153 
Since ILs containing small halide anions generally exhibit 
strong electrostatic interactions due to the small anion radius, 
they are effective for protein dissolution.140,154 Likely, the 
interaction of the ions with the hydrophilic or hydrophobic 
amino acid moieties of the protein entity is much more 
significant than ion-induced long-range disruption of the 
surrounding water structure.1,35,125,140,155
The biomolecular interactions between ILs and 
protein entities are, thus, complex, with all the current 
scientific literature ending at the similar conclusion that 
the stabilization/destabilization of the protein entities 
depends on the selectivity between ILs and proteins. Such 
consensus requires, of course, additional research. Baker 
and Heller156 showed that the interaction between protein 
moieties and ILs not only caused significant unfolding 
of the (secondary domain) α-helical structures of the 
protein moieties, but also changed their aggregation state, 
suggesting that the aforementioned interaction depends on 
the protein sequence. Additionaly, the type of ILs ions does 
play an important role in affecting the protein biological 
and conformational structure, presumably either by direct 
interaction with the protein moieties or by modification of 
the microenvironment in, and around, the protein moiety, 
due to their different physicochemical properties.84,157 
Notwithstanding the fact that the anions in ILs are 
significant for the protein stabilization, the contributing 
effect of the alkyl chain in the cation cannot be ignored.39,158
When the protein entity is in an aqueous environment, 
the role of the (aqueous) solvent in the stabilization of 
the protein structure is of utmost importance,34 making 
it important to understand the rearrangement of solvent 
molecules (water) in the presence of co-solutes (as for 
example ILs) at a molecular level (see Figure 2). In the 
liquid state, water displays asymmetry between the donor 
and acceptor in hydrogen bonding,1,159 with the difference 
in the orientation of water molecules towards polar/
apolar solutes being one of the factors responsible for the 
solubility behavior of a given solute in aqueous medium, 
thus playing a major role in the structure, stabilization and 
function of biological macromolecules.8,34 The effects of 
both polar and apolar solutes upon water structure has been 
duly reviewed by Sharp and Vanderkool,160 where they 
tackled the structure and solvation of water molecules, 
where the water is a highly cohesive and interacting 
three-dimensional network of hydrogen bonding groups. 
A weakly interacting apolar moiety can only insert itself 
by displacing the weaklier coordinated water molecules 
that produce larger hydrogen bond angles. On the other 
hand, polar groups with their strong electrostatic fields 
tend to align solvating water molecules in a way that 
they make more strained hydrogen bonding with each 
other.1,35,125,161,162 Thus, direct electrostatic interactions 
occur between protein hydrophilic groups, as a result of 
the dieletric shielding between proteins provided by the 
hydrogen-bond networks.15,163-165 Overall, if the hydrogen 
bonding between water molecules is weaker, they are more 
labile to disruption by temperature and solutes.125,160,166,167 
Water has long been thought as the unique solvent for 
biomolecules and biosystems, since it is fundamental 
in protein folding mainly because of its role in defining 
hydrophobic attractions168 that are responsible for the 
rapid gluing of hydrophobic sites. Long ago, Luscher and 
Ruegg169 proposed a model for the interaction of water 
molecules with the native protein three-dimensional 
architecture, with the experimental results suggesting 
that the interaction between the first monolayer of water 
molecules with the surface of the protein is responsible 
for major conformational changes in the native structure 
of the protein molecule.170,171 Such arrangement of water 
molecules surrounding the protein surface was then 
designated to be the hydration shell.1,35,125,172-174 The 
formation of the hydration layer is mainly responsible for 
the large values in excluded volume for the proteins in 
the presence of stabilizing agents.175-177 On the contrary, 
denaturing agents promote large fluctuations in the 
hydration layer of water molecules that can prevent protein 
dynamics, affecting its function.178,179 The presence of 
solutes also disturbs the angular structure of water.160,180
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When talking about ILs and water, their interactions are 
far more complex and are highly dependent on the nature 
of ILs’ constituent ions. According to the law of matching 
affinities postulated by Collins,181 the nature of the cation-
anion interactions in an ionic compound is also responsible 
for the change in protein stability in ionic solutions. 
According to the Collins’ rationale,181 stabilization and 
crystallization of proteins are both related with a decrease 
in the solvent accessibility to the protein surface, while 
with the increase of solvent-surface protein accessibility 
causes destabilization and solubilization. Collins181 
demonstrated that combinations of chaotropic-chaotropic or 
kosmotropic-kosmotropic cation-anion lead to weak ions-
water molecules interactions, since the oppositely charged 
ions of the dissolved ionic compound tend to stay together. 
While the miscibility behavior with water is simply related 
to the hydrophobicity of the cation (or to the hydrophobicity 
of the anion, in this case reducing the water solubility of the 
ILs), such behavior is more complex for ILs with varying 
anions, due to pronounced anion-water interactions.21,39 
The interaction of ILs with the protein surface is a complex 
result of the ability of their ions to disrupt the hydrogen 
bonding, to promote non-polar interactions, and to induce 
electrostatic effects that contribute to protein stability. ILs 
are thus considered as interesting solvents for biological 
systems and, due to their unique properties and large variety 
of potential applications, they have been widely used in 
enzyme catalysis and protein stabilization, solubilization, 
crystallization and separations.
Protein entities are one of the most important 
biomacromolecules of living beings, possessing highly 
relevant clinical, biochemical, biotechnological and genetic 
features. As protein entities exhibit admirable biological 
properties, their production and applications have grown 
very rapidly in different fields such as in biochemical 
research, chemical, food and (bio)pharmaceutical 
industries.1,34,35,39,84,123,152 Due to the wide range of their 
potential applications, it is fundamental to maintain 
the three-dimensional architecture of protein moieties 
through weak interactions such as hydrogen bonds, and 
hydrophobic and electrostatic interactions. Small changes 
in the protein microenvironment disrupt such weak 
interactions causing their denaturation, which in turn leads 
to the unfolding of the three-dimensional architecture and 
concomitant inactivation.126,129,152,182 To overcome these 
issues, several strategies to stabilize proteins outside their 
native (physiological) conditions have been developed,34 
such as, chemical modification, immobilization (either 
via entropic confinement or through establishment of 
multipoint covalent bonding to macroscopic insoluble 
supports), genetic modification, or addition of stabilizing 
agents, while the protein is still in its native (active) three-
dimensional conformation. Some of these strategies are 
quite effective, however, do not prevent the irreversible 
thermal denaturation of proteins.35,130,132,133 The half-lives 
of many proteins, including therapeutic ones, can be 
increased by lyophilization (freeze-drying).34 In order to 
increase the solubility and to prevent denaturation and 
aggregation of therapeutic proteins, some excipients like 
sugars, salts and amino acids have been used in commercial 
formulations.34,125 However, such excipients also fail to 
provide reasonable long-term stability to some therapeutic 
proteins.35,138 Considering these assumptions, ILs have been 
emerging as very feasible solvents either for performing 
enzymatic reactions123,183,184 or for other protein-based 
applications.185-187 Although ILs are capable of stabilizing 
protein entities over a wide range of temperatures, the 
thermal stability of these biomacromolecules depends 
on the correct choice of ILs employed, since proteins are 
not homogeneously stable in all ILs-classes. In general, 
proteins’ stability and activity are mainly affected by 
polarity, hydrophobicity and hydrogen-bonding capability 
of ILs ions. Thus, it is evident that the solubility and 
stability of protein entities in ILs heavily depends on 
the type of cation and anion. ILs containing chaotropic 
cations (bulky, low-charged and weakly-hydrated ions 
that decrease the structure of water) and kosmotropic 
anions (small-sized, highly-charged and strongly-hydrated 
ions that increase the structure of water) are described 
as optimal biomacromolecules stabilizers.39,125,174,181,187 
ILs enhance protein stability, maintaining their three-
dimensional structure188 and, due to their high solvation 
capability, enabling the solubilization of protein entities. 
Upon solubilization in ILs, protein aggregation is 
prevented, which contributes thereby to the increase in the 
stability and biological activity of the protein.35,188 Several 
researchers145,148,189 demonstrated that the hydrophobic IL 
1-butyl-3-methylpyridinium bis(trifluoromethylsulfonyl)
imide ([BMPy][NTf2]) can be used to dissolve a 
small amount of the protein monellin. Other published 
papers35,140,190,191 report the use of additional structures to 
stimulate protein solubilization in hydrophobic ILs.
These features of ILs have helped in preparing liquid 
formulations of therapeutic proteins, which is actually 
one of the major hurdles in the use of protein-based 
therapeutics. Such biocompatible ILs solvate and stabilize 
therapeutic proteins, opening up a new window in the (bio)
pharmaceutical industry.35,123,138,192,193 A potential rationale for 
the mechanism underlying the increased protein solubility 
in ILs could be the replacement of a hydrophobic site in the 
protein moiety with an ion from the IL and concomitant 
reduction of the likelihood that site would subsequently 
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participate in nonspecific interactions. If the formation of 
structured crystals is regarded as a kinetic process, where 
the rate of formation of amorphous precipitate competes 
with that for formation of crystalline structures, then raising 
the solubility or reducing nonspecific binding between 
hydrophobic sites would effectively slow down the protein 
self-aggregation processes, leading to enhanced stability. 
ILs can also be used as alternative reaction media solvents 
for biocatalysis and biotransformation reactions,8,76 with 
several researchers5,17,43,76,77,80,194-202 demonstrating that ILs 
play an important role in increasing the activity, stability 
and enantioselectivity of enzymes. The enhancement 
observed in the activity and stability of protein entities 
seems to be associated with both maintenance of 50% 
of the initial α-helix content and the enhancement of 
β-strands of the enzyme molecule at 50 °C, resulting in 
a more compact enzyme conformation while still being 
able to display catalytic activity.144 Potdar et al.203 provided 
an overview with special emphasis on the application of 
enzyme-catalyzed reactions and separation processes 
employing ILs. ILs are, therefore, effective in increasing 
enzyme (thermal) stability and selectivity and maintain a 
high enzymatic efficiency with greater reaction rates at 
high substrate concentrations, and with shorter reaction 
times.8,39,106,204
5. Future Trends
Advances in the field of structural and functional 
stabilization of protein entities, such as enzymes, 
recombinant proteins, bioactive peptides, bacteriophage 
particles, or protein-based antibiotics, using tailor-made 
ILs, will enable not only the solubilization and stabilization 
of those entities, but also their incorporation into liquid 
formulations for biopharmaceutical applications. Bearing in 
mind that all protein entities share common features related 
to their intrinsic instability when put in environments 
displaced from their native physiological conditions, 
and because the latest advances in biopharmaceutical 
production allows guessing an increase in the use of 
protein-based biopharmaceuticals, full structural and 
functional stabilization of said biomolecules will be of 
utmost importance. In this line of thinking, although ILs can 
exert both stabilizing (by solubilizing protein moieties, thus 
preventing their self-aggregation) and destabilizing effects 
on protein moieties, depending on their physico-chemical 
properties, tailoring of such highly viscous liquid salts 
to less viscous, hydrophobic ones, containing chaotropic 
cations and kosmotropic anions, will allow to optimally 
stabilize protein entities up to a wide range of temperatures 
and for extended periods of time.
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